期刊文献+

干扰素α对慢性髓系白血病来源的树突状细胞表达Fas/FasL的影响(英文) 被引量:2

Influence of Interferon α on Expression of Fas and Fas Ligand in Dendritic Cells from Patients with Chronic Myeloid Leukemia
下载PDF
导出
摘要 本研究探讨干扰素α对慢性髓系白血病(CML)来源的树突状细胞(DC)表达Fas/FasL的影响。在CML-DCs的培养液中除加入SCF,GM-CSF,TNF-α及IL-4外,还加入IFN-α。培养10-14天,除了鉴定细胞免疫表型和Ph1染色体比例外,还应用流式细胞仪检测细胞表达Fas/FasL比例,用PI染色分析细胞凋亡,ELISA法检测上清液sFas含量。结果表明:加入IFN-α后,CML-DC共刺激分子的表达显著改善,Ph1(+)细胞比例随IFN-α浓度增加而减低;培养细胞Fas的表达上调,sFas含量却下降,FasL表达阴性,细胞凋亡比例增加。结论:IFN-α在改善CML-DC表型同时,可通过Fas途径促进Ph1(+)细胞凋亡,使Ph1(-)细胞数量相对增加。 The study was aimed to investigate the influence of interferon α (IFN-α) on the expressions of Fas and Fas ligand (FasL) in dendritic cells (DCs) from patients with chronic myeloid leukemia (CML). In addition to adding stem cell factor( SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor α (TNF- α) and interleukin 4 ( IL-4), the IFN-α was added to the serum-free medium for DCs. After culturing for 10-14 days, cell phenotype and percentage of Ph1 chromosome were detected by different methods. The expression of Fas or FasL on CML-DCs and cell cycle of DCs labeled with propidium iodine (PI) were measured by flow cytometry. The concentra- tion of sFas in supernatants was analyzed by enzyme-linked immunosorbent assay (ELISA). The results indicated that the expression of co-stimulatory molecules were improved significantly while the percentages of Ph1 positive cells decreased. The level of Fas on cells was up-regulated and the concentration of sFas decreased. However, the expression of FasL was negative. The ratio of apoptosis rose gradually while the concentration of IFN-α increased. It is concluded that IFN-α can accelerate the apoptosis of Ph1 positive cells through Fas/FasL pathway, so the number of Ph1 negative cells increases relatively.
出处 《中国实验血液学杂志》 CAS CSCD 2008年第3期501-505,共5页 Journal of Experimental Hematology
关键词 干扰素Α 慢性髓系白血病 树突状细胞 FAS/FASL interferon α chronic myeloid leukemia dendritic cell Fas/FasL
  • 相关文献

参考文献18

  • 1Wang C, Al-Omar HM, Radvanyi L, et al. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cell stimulatory activity by IFN-α. Exp Hematol, 1999 ;27 : 1176 - 1184.
  • 2Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood, 2001 ; 98:2603 -2614.
  • 3Jorgensen HG, Holyoake TL. A comparison of normal and leukemic stem cell biology in chronic myeloid leukemia. Hematol Oncol, 2001 ;19:89 - 106.
  • 4Selleri C, Sato T, Del-Vecchio L, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia. Blood, 1997 ; 89: 957 - 964.
  • 5Zhao W, Xiang P, Wei X, et al. Serum-free culture of dendritic cells from patients with chronic myeloid leukemia in vitro and estimation their cytotoxicity. Chin Med J ( Engl), 2002 ; 115,1296 - 1300.
  • 6Talpa M, Estrow Z, Kantarjian H, et al. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. J Clin Invest, 1994; 94 : 1383 - 1389.
  • 7Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998 ; 58:2489 - 2499.
  • 8Brossart P, Wirths S, Brugger W, et al. Dendritic cells in cancer vaccines. Exp Hematol, 2001 ;29 : 1247 - 1255.
  • 9Selleri C, Maciejewski JP, Pane F, et al. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Blood, 1998 ;92:981 -989.
  • 10Buzyn A, Petit F, Ostankovitch M, et al. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: a mechanism of tumor immune escape in leukemia patients. Blood, 1999 ;94:3135 - 3140.

同被引文献21

  • 1张在云,吴金民.白细胞介素-18基因转染的肺癌细胞与树突状细胞融合体的抗肿瘤作用[J].中华肿瘤杂志,2007,29(1):17-20. 被引量:10
  • 2Martin-Ayuso M, Almeida J, Perez-Andres M, et al. Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired. Oncologist, 2008 ; 13 ( 1 ) : 82 - 92.
  • 3Kremser A, Dressig J, Grabrucker C, et al. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS : an evaluation of different methods. J Immunother, 2010 ;33 (2) : 185 - 199.
  • 4Brauer KM, Werth D, von Schwarzenberg K, et al. BCR-ABL activity is ritical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res, 2007 ;67 ( 11 ) :5489 - 5497.
  • 5Larmonier N, Janikashvili N, LaCasse C J, et al. Imatinib mesylate inhibits CD4^+CD25^+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J Immunol, 2008;181 (10) :6955 -6963.
  • 6Boasso A, Hardy AW, Anderson SA, et al. Hiv-induced type Ⅰ interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PloS One, 2008 ;3 ( 8 ): e2961.
  • 7Brandacher G, Caker F, Winkler C, et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int, 2007;71 ( 1 ) :60 -67.
  • 8Katz JB, Muller A J, Prendergast GC, et al. Indoleamine 2,3- dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev, 2008 ;222(2) :206 -221.
  • 9Curti A, Trabanelli S, Salveetrini V, et al. The role of indole- amine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood, 2009 ; 113 ( 11 ) :2394 - 2401.
  • 10Liu X, Shin N, Koblish HK, et al. Selective inhibition of indoleamine 2, 3-dioxygenase ( IDOl ) effectively regulates mediators of anti-tumor immunity. Blood, 2010 ; 115 ( 17 ) : 3520 - 3530.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部